


# SEEN & HEARD



## Evaluating the Safety of Netarsudil

Francis Mah, MD, joins Neda Shamie, MD, on *Clinical Minute* to discuss a post hoc analysis of data from a phase 3 evaluation of the safety of netarsudil 0.02% compared to timolol 0.5%.



## Meeting Updates

- **AGS Annual Meeting** | March 2-5, 2023; Live in Austin & Virtual
- **YoungMD Connect Live** | March 24-26, 2023; Live in Austin
- **ASCRS Annual Meeting** | May 5-8, 2023;  
Live in San Diego
- **World Glaucoma Congress** | June 28-July 1;  
Live in Rome



© iStockphoto.com

# SURVEY SAYS

## Survey Says: Procedure and IOL Selection

On a recent episode of "Survey Says" With I. Paul Singh, MD, a special edition of *GT: The Podcast*, Dr. Singh is joined by guests Shamil Patel, MD, MBA, and Manjool Shah, MD. The surgeons discuss how they would approach procedure and IOL selection for a real patient case, and later, they find out how their colleagues chose to proceed based on the results of a social media poll of *GT's* audience.



Senior residents, fellows, and new practitioners (first 1-5 years in practice) are invited to participate in an in-person IOL & Biometry Master Class on Friday, March 24 at YoungMD Connect Live in Austin. Space is limited; to register, visit [bit.ly/YMDCIOL](https://bit.ly/YMDCIOL).



Friday, March 24  
3-6 PM CT | Austin, TX  
Register at [bit.ly/YMDCIOL](https://bit.ly/YMDCIOL)



SpyGlass Pharma released 6-month data from a first-in-human glaucoma treatment trial showing that its drug delivery platform continues to demonstrate significant IOP lowering in patients with glaucoma or ocular hypertension, according to a company news release. The data were showcased by Malik Y. Kahook, MD, at the Glaucoma 360 New Horizons Forum in San Francisco. For more, visit [bit.ly/GTJFSpyglass](https://bit.ly/GTJFSpyglass).



Malik Y. Kahook, MD @MalikKahook · Feb 3

"Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months." We are now in a new era of targeted long-term drug delivery.

[spyglasspharma.com](https://spyglasspharma.com) @CUEyeCenter



[globenewswire.com](https://globenewswire.com)

SpyGlass Pharma Unveils 6-Month Data from the...  
Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% ...